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The long path of human placenta, 
and its derivatives, in regenerative 
medicine
Antonietta R. Silini , Anna Cargnoni , Marta Magatti , Stefano Pianta and Ornella Parolini*
Centro di Ricerca “E. Menni”, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy
In the 1800s, a baby born with a caul, a remnant of the amniotic sack or fetal membranes, 
was thought to be lucky, special, or protected. Over time, fetal membranes lost their leg-
endary power and were soon considered nothing more than biological waste after birth. 
However, placenta tissues have reclaimed their potential and since the early 1900s an 
increasing body of evidence has shown that these tissues have clinical benefits in a wide 
range of wound repair and surgical applications. Nowadays, there is a concerted effort 
to understand the mechanisms underlying the beneficial effects of placental tissues, and, 
more recently, cells derived thereof. This review will summarize the historical and current 
clinical applications of human placental tissues, and cells isolated from these tissues, 
and discuss some mechanisms thought to be responsible for the therapeutic effects 
observed after tissue and/or cell transplantation.
Keywords: human term placenta, amniotic and chorionic membranes, umbilical cord, stem cells, clinical trials, 
immunomodulation, paracrine effect, regenerative medicine
A SHORT HiSTORY OF THe CLiNiCAL USeS OF HUMAN  
TeRM PLACeNTA
Human placenta has been traditionally used in Chinese medicine for centuries. The Compendium of 
Materia Medica was published in 1593 by one of the first and greatest biologists and pharmaceuti-
cal experts of China, Li Shi-Zhen (Figure 1). This medical text is a Chinese record of substances 
with medical properties, and it contains a section entirely devoted to the medical uses of human 
placenta “zi he chi” as a medicine (Young and Benyshek, 2010). At that time, eating the placenta 
was thought to be beneficial but since then there has been a shift of paradigms in which scientific 
rationale supports clinical benefit of placental tissues, or derivatives, for treating patients afflicted 
by a variety of diseases. As discussed below, the earliest reported applications of the placenta (after 
Li Shi-Zhen’s) were focused on fetal membranes. The first reports showing that the placenta also 
harbors cells, which could have stem/progenitor properties, ultimately giving rise to their potential 
use in regenerative medicine, were published many years later (Figure 1), (Bailo et al., 2004; Fukuchi 
et al., 2004; Igura et al., 2004; In ‘t Anker et al., 2004; Soncini et al., 2007; Troyer and Weiss, 2008).
The first documented use of fetal membranes as a surgical material in skin transplantation came 
more than 3 decades after the placenta was initially reported to possess medicinal properties. In 1910, 
Davis (1910) showed that the use of amniotic membrane (AM) in skin grafting gave superior results 
when compared to xenograft or cadaveric coverings. Shortly afterwards in 1913, Stern (1913) and 
Sabella (1913) reported the use of the AM for treating skin wounds. They applied intact amniotic tissues 
to skin burns and ulcers and then covered them with dressings. Upon removal of the dressings 2 days 
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later, the authors reported that the amnion had integrated with the 
patient’s tissues. They also reported lack of infection, a significant 
decrease in pain, and an increased rate of re-epithelialization of the 
traumatized skin surface in patients treated with amnion.
More than 20 years passed before another study would report 
the use of amniotic tissues for wound repair or surgery. Around 
1940, the AM was increasingly being used successfully in different 
applications. In the late 1930s, Brindeau (1934) and Burger (1937) 
reported the successful use of amnion for vaginal reconstruction 
surgery in a patient with Mullerian agenesis. Shortly afterwards, 
the AM was first applied in ophthalmology to repair conjunctival 
defects (De Rotth, 1940) and burns (Sorsby and Symons, 1946; 
Sorsby et al., 1947). Ophthalmology would later go on to be one 
of the most popular applications of the AM to date.
Following these and other studies, between 1940 and 1970, a 
number of clinical trials were published reconfirming the suc-
cessful use of the AM for skin injuries. In 1940, the first paper 
was published describing the use of amnion for the prevention 
of meningocerebral adhesions following head injury. The authors 
reported lack of adhesions and lack of rejection 60  days after 
surgery, and “disappearance” of the amnion after 30 days (Chao 
et al., 1940). Later that decade, and following Burger’s work on 
vaginal reconstruction, Kubanyi (1947) used amnion in patients 
undergoing abdominal surgery with an enterocutaneus fistula 
secondary to surgery for lysis of adhesions. After closing the 
small bowel fistula, the small area of the bowel was wrapped with 
amnion, and notably, patients were discharged on a regular diet 
only 12 days after surgery. Importantly, Dino et al. (1965) showed 
that AM from routine deliveries could be sterilized and kept for 
FiGURe 1 | Historical uses of human term placental tissues and cells derived thereof. 1Chinese medical text published in 1593 by Li Shi-Zhen; 2Davis (1910) 
and Stern (1913) and Sabella (1913); 3Brindeau (1934) and Burger (1937); 4De Rotth (1940), Sorsby and Symons (1946); Sorsby et al. (1947); 5Dino et al. (1965); 
6Trelford-Sauder et al. (1977); Trelford-Sauder et al. (1978), Silverton et al. (1979); Dhall (1984), Nisolle and Donnez (1992), Georgy and Aziz (1996), Gharib et al. 
(1996); 7Trelford-Sauder et al. (1978); Muralidharan et al. (1991), Young et al. (1991); Arora et al. (1994), Rennekampff et al. (1994); 8Troensagaard-Hansen (1950); 
Bennett et al. (1980), Subrahmanyam (1995); 9Gruss and Jirsch (1978) and Bose (1979); 10Lee and Tseng (1997); Tseng et al. (1997), 11, 12 reviewed in Fetterolf and 
Snyder (2012).
6 weeks at 4°C and safely used on acute second degree burns and 
on skin donor sites (Dino et al., 1965). This was one of the first 
reports which suggested handling procedures for the AM, which 
in turn fueled even more interest among clinicians in using the 
AM for treating skin lesions.
In 1972, Trelford et al. (1972) used human amnion in sheep, 
and confirmed previous findings that as a surface graft, amnion 
was able to reduce pain, decrease infection, and reduce the loss 
of fluids. Also in 1972, Robson and his colleagues began to 
study the use of AM for severe burns and skin injuries. Similar 
to Trelford, they reported notable pain relief and immediate 
adherence of the AM dressing to the wound. Interestingly, the 
membranes were easily peeled off 1 week after application and, 
according to Robson, spontaneous re-epithelialization had 
occurred underneath the membranes. Later that decade, in 
1977, Trelford-Sauder et  al. (1977) reported the successful use 
of amnion to replace pelvic peritoneum in patients who had 
exenterative procedures. Following these and other observations, 
there was an exponential increase of published clinical studies, 
which reconfirmed the successful application of fetal membranes 
in diverse clinical indications, including burns (Gruss and Jirsch, 
1978; Bose, 1979), ulcers (Troensagaard-Hansen, 1950; Bennett 
et al., 1980; Subrahmanyam, 1995), surgical reconstruction of the 
vagina (Dhall, 1984; Nisolle and Donnez, 1992; Georgy and Aziz, 
1996), abdominal surgery (Trelford-Sauder et al., 1978; Silverton 
et al., 1979; Gharib et al., 1996), and other surgical procedures 
for the prevention of adhesions (Trelford-Sauder et  al., 1978; 
Muralidharan et al., 1991; Young et al., 1991; Arora et al., 1994; 
Rennekampff et al., 1994).
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The 1990s can be considered the beginning of modern his-
tory on the use of AM in ophthalmology (Dua et al., 2004). In 
this decade, Dr. Tseng, an ophthalmologist from Miami, applied 
for Human Cell Tissue Products (HCT/P) regulatory status for 
the use of amniotic tissues in ocular repair. In 1999, Dr. Tseng’s 
proposal was rejected by the US Food and Drug Administration’s 
(FDA) tissue reference group stating “Amniotic membrane for 
ocular surface reconstruction is considered a tissue under the 
current code of federal regulations (CFR) at 21 CFR Part 1270, 
but the intended use would be non-homologous when 21 CFR 
Part 1271 becomes effective” (Lee and Tseng, 1997; Tseng et al., 
1997). Dr. Tseng appealed the ruling and 1 year later, the FDA 
reversed the prior ruling stating that “Allogeneic amniotic mem-
brane for ocular repair is considered to be a section 361 HCT/P 
if the product’s advertising is restricted to homologous use for 
wound covering.” The two main points made by the FDA were 
that it had to be used as a covering and must be acellular, whereas 
“Amniotic membrane cultured with stem cells for ocular repair 
is considered to be a biologic product subject to Investigational 
New Drug and Biologic License Application.” From that point 
on, the use of AM in ophthalmic surgery catapulted. Nowadays, 
there are over 45,000 applications used by the ophthalmologists, 
including conjunctival reconstruction, burn treatment, glaucoma 
surgery, and wound healing (Fetterolf and Snyder, 2012).
CURReNT CLiNiCAL APPLiCATiONS 
OF PLACeNTA
The twenty-first century marks another turning point in which 
the use of cells isolated from different placental regions are being 
progressively more investigated and used for their therapeutic 
potential. These studies have paved the way for what are now 
considered established clinical uses and investigative clinical 
trials. Placental tissues, and cells derived thereof, are nowadays 
interesting therapeutic biomaterials currently used in the clinic. 
The renewed interest in using the AM in a number of applications 
has been favored by the development of improved techniques 
for both membrane cryopreservation (Lee and Tseng, 1997) 
and advanced isolation and culture procedures for cells derived 
thereof.
established Clinical Applications
Recent advances in tissue preservation techniques, accompanied 
by evidence of therapeutic effects, have resulted in commercially 
available AM products for use in patients. A repertoire of data 
shows that these products promote rapid and complete healing 
of wounds.
Without a doubt, the AM is widely utilized in the field of 
ophthalmology. The AM is routinely used as a graft, spread onto 
the ocular surface to treat epithelial defects or ulcers, or as a band-
age to cover the ocular surface to promote healing. An infinite 
number of ocular pathologies are being treated with the AM, such 
as corneal epithelial defects, corneal ulcers, glaucoma, pterygium, 
and bullous keratopathy (Dua et  al., 2004; Liu et  al., 2010; 
Riau et al., 2010; Kesting et al., 2014). Furthermore, the AM is 
also making its way in dermatology, where it can be used to cover 
burns and to treat chronic ulcers (Lo and Pope, 2009), and in 
multiple surgical procedures, some of which already mentioned, 
and others, such as the prevention of post-operative adhesions. 
The increasing number of case studies will surely support the 
establishment of a routine use also in the latter two applications.
Clinical Trials
At the time this review was written, 95 clinical trials evaluating 
placental cells or AM (Figure 2; Tables 1–5) were registered on 
the NIH Clinical Trials website (https://clinicaltrials.gov).
Surely, there has been much progress since the first docu-
mented use of fetal membranes in the early 1900s, and there 
have been significant advances in the preparation of amniotic 
and chorionic membranes for clinical use. In fact, there are many 
companies which commercialize fetal membranes and/or their 
derivatives, such as Bio-Tissue®, a subsidiary of TissueTech™ 
(Prokera®, Amniograft®, Amnioguard®), IOP Ophthalmics 
(AmbioDisk™, Ambio2™), MiMedx® (Epifix®, Amniofix®), 
Liventa Bioscience (AmnioClear™), Amniox Medical (NEOX® 
CORD 1K, Clarix™1K), and NuCel (ReNu™ amniotic allograft), 
just to name a few.
Recently published reports have provided consistent evi-
dence of the therapeutic benefit of the AM graft. For example, 
the AM has been successfully used in patients with bullous 
keratopathy (NCT01926535, completed, Table  1), and the 
results suggested that the technique is safe and represents an 
efficient alternative to the use of therapeutic contact lenses for 
the relief of ocular pain in these patients (Venegas et al., 2014). 
In a different study (NCT00659308, completed, Table 1), the 
AM was shown to be comparable to anterior stromal puncture 
in the management of pain in patients with bullous keratopathy 
(Paris Fdos et al., 2013). When tested in patients with scleral 
thinning, the AM was not as effective as lamellar corneal and 
scleral transplantation (de Farias et al., 2014), but a phase II/III 
trial is now enrolling patients for further testing (NCT00801073, 
Table 1).
The use of a dehydrated human amnion/chorion membrane 
Epifix® (MiMedx®) has been reported to enhance healing and 
promote complete epithelialization of diabetic foot ulcers 
(NCT01552499, completed, Table  2) (Zelen et  al., 2014) and 
to reduce wound size and improve healing also in patients with 
venous leg ulcers, both when compared to standard treatment 
(NCT01552447, completed, Table 2) (Serena et al., 2014). This 
same group also investigated the use of Amniofix® (MiMedx®), 
a dehydrated human amniotic/chorionic membrane refined 
by a micronization process, in patients with plantar fasciitis 
(NCT01659827, completed, Table  3) (Zelen et  al., 2013). They 
reported reduced pain and improved physical and mental scores 
(evaluated by a health survey) versus controls. Interestingly, 
bovine AM (NCT01895374, completed, Table 2) has been tested 
for the treatment of laser-induced skin wounds, showing once 
again quicker epithelialization when compared to hydrocolloid-
treated wounds (Min et  al., 2014), suggesting that xenogenic 
material can also be used in wound treatment.
As mentioned above, the interest in using cells isolated from 
different placental regions intensified in the twenty-first century. 
Different types of placenta-derived cells and factors are being 
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tested in clinical trials. They come from either fetal placental tis-
sues (such as amnion and chorion) or from maternal tissues (such 
as decidua). For example, PLX-PAD (PLacental eXpanded adher-
ent stromal cells produced by Pluristem Inc.) are isolated from 
human placenta by enzymatic digestion of both maternal and 
fetal tissues (Ramot et al., 2009; Kranz et al., 2010). PLX-PAD cells 
have been used in two clinical trials to treat critical limb ischemia 
(NCT00919958, completed; NCT00951210, completed), and are 
now being tested for the treatment of intermittent claudication 
(NCT01679990, recruiting) and pulmonary arterial hypertension 
(NCT01795950, active) (Table 5). Thus far, no results have been 
published for the completed trials.
PDA-001/PDA-002 are culture-expanded mesenchymal-like 
cells produced by Celgene Cellular Therapeutics. The safety 
and efficacy of PDA001 cells have been studied in patients with 
Crohn’s Disease (Mayer et al., 2013) (NCT01155362, completed; 
NCT01769755, completed), ischemic stroke (NCT01310114, 
terminated by sponsor), pulmonary sarcoidosis (NCT01440192, 
FiGURe 2 | Registered clinical trials using placenta-derived cells or amniotic membrane. The search was performed in June 2015 on the U.S. National 
Institutes of Health clinical trials website using: placental-derived cells OR amniotic membrane, which resulted in 240 clinical trials. After excluding those with 
unknown status (which resulted in 196) and irrelevant ones, the search resulted in 95 clinical trials. For each disease application specified in small boxes, n = 1 
unless otherwise specified. PAD, peripheral arterial disease; EB, epidermolysis bullosa; IPF, idiopathic pulmonary fibrosis; RA, rheumatoid arthritis; GvHD, graft 
versus host disease *Includes two published clinical trials not registered on NIH website (diabetes and multiple sclerosis).
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terminated by sponsor), and active rheumatoid arthritis 
(NCT01261403, terminated) (Table 5). Published results obtained 
from the Phase I trial (NCT01769755) in patients with Crohn’s 
disease (Mayer et  al., 2013) show that out of the six patients 
treated with low dose and six with high dose, all low dose and 
two high dose patients responded to the treatment (defined as 
≥70 point decrease from baseline in disease activity score). Some 
minor evidence of infusion-related events, fever, and headache 
were reported, but no patient withdrew from the study, and 
PDA001 was well-tolerated (Mayer et al., 2013). A Phase II study 
(NCT01155362) investigating PDA001 in treatment-resistant 
Crohn’s disease has just been completed, but results are not yet 
available. PDA001 cells have also been recently tested in patients 
with multiple sclerosis (Lublin et al., 2014). The published results 
showed that in all 16 patients, none developed 5 or more new lesions 
in 2 consecutive monthly MRI scans during a 6-month follow-up. 
Some infusion-related adverse events, such as hematoma and 
swelling, occurred and settled without medication. This study is 
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tested in clinical trials. Th
ey com
e from
 either fetal placental tis-
sues (such as am
nion and chorion) or from
 m
aternal tissues (such 
as decidua). For exam
ple, PLX-PAD
 (PLacental eXpanded adher-
ent strom
al cells produced by Pluristem
 Inc.) are isolated from
 
hum
an placenta by enzym
atic digestion of both m
aternal and 
fetal tissues (Ram
ot et al., 2009; Kranz et al., 2010). PLX-PA
D
 cells 
have been used in tw
o clinical trials to treat critical lim
b ischem
ia 
(N
CT00919958, com
pleted; N
CT00951210, com
pleted), and are 
now
 being tested for the treatm
ent of interm
ittent claudication 
(N
CT01679990, recruiting) and pulm
onary arterial hypertension 
(N
CT01795950, active) (Table 5). Th
us far, no results have been 
published for the com
pleted trials.
PD
A-001/PD
A-002 are culture-expanded m
esenchym
al-like 
cells produced by C
elgene C
ellular Th
erapeutics. Th
e safety 
and effi
cacy of PD
A
001 cells have been studied in patients w
ith 
Crohn’s D
isease (M
ayer et al., 2013) (N
CT01155362, com
pleted; 
N
CT01769755, com
pleted), ischem
ic stroke (N
CT01310114, 
term
inated by sponsor), pulm
onary sarcoidosis (N
CT01440192, 
FiG
U
R
e
 2 | R
eg
istered
 clinical trials using
 p
lacenta-d
erived
 cells o
r am
nio
tic m
em
b
rane. The search w
as perform
ed in June 2015 on the U
.S
. N
ational 
Institutes of H
ealth clinical trials w
ebsite using: placental-derived cells O
R
 am
niotic m
em
brane, w
hich resulted in 240 clinical trials. A
fter excluding those w
ith 
unknow
n status (w
hich resulted in 196) and irrelevant ones, the search resulted in 95 clinical trials. For each disease application specified in sm
all boxes, n =
 1 
unless otherw
ise specified. PA
D
, peripheral arterial disease; E
B
, epiderm
olysis bullosa; IP
F, idiopathic pulm
onary fibrosis; R
A
, rheum
atoid arthritis; G
vH
D
, graft 
versus host disease *Includes tw
o published clinical trials not registered on N
IH
 w
ebsite (diabetes and m
ultiple sclerosis).
TABLe 1 | Clinical trials using placenta-derived cells, fetal membranes, or derivatives in ophthalmic disorders.
Condition Clinical trial iD Phase Materials used Status Sponsor Results/status or remarks
Scleral thinning NCT00801073 II/III AM graft Enrolling Federal University of São Paulo, Brazil Primary Completion Date: February 2005, last verified December 
2008 (de Farias et al., 2014)
Bullous 
keratopathy
NCT01926535 II AM graft Completed Universidad de Valparaiso, Chile None available, Study Completion Date: June 2012
NCT00659308 ns AM Completed Federal University of São Paulo, Brazil Study Completion Date: June 2007, last verified January 2008 (Paris 
Fdos et al., 2013)
Pterygium or 
ocular surface 
cicatrizing 
diseases or 
keratitis
NCT02102776 ns AM Not yet recruiting Shiyou Zhou, Sun Yat-sen University, China Estimated Study Completion Date: September 2016
NCT01319721 ns AM graft Completed Shiyou Zhou, Sun Yat-sen University, China Results available online (https://clinicaltrials.gov), Study Completion 
Date: June 2014
NCT00457223 II/III AM Completed Chulalongkorn University, Thailand None available, study completed in 2007
NCT00802620 I AM Enrolling Federal University of São Paulo, Brazil None available, Primary Completion Date: June 2005, last verified 
December 2008
NCT02015000 ns AM Recruiting National Taiwan University Hospital, Taiwan Estimated Study Completion Date: November 2014, last verified 
December 2013
NCT00383825 ns AM Completed Baskent University, Ankara, Turkey None available, Estimated Study Completion Date: December 2004, 
last verified October 2006
NCT00344201 I AM Completed Singapore National Eye Centre, Singapore None available, Study Completion Date: January 2008
NCT02116062 ns AM Recruiting University Hospital, Strasbourg, France Estimated Study Completion Date: March 2016
Corneal wounds 
or ulcers or 
epithelial defects
NCT00915759 ns ProKera® Active Walter Reed National Military Medical Center, 
Washington, DC, USA
Estimated Study Completion Date: December 2014, last verified  
July 2014
NCT02168790 0 Amnioclip ring 
system
Completed Klinikum Chemnitz gGmbH, Germany None available, Study Completion Date: August 2013
NCT00238862 ns AM Completed King Khaled Eye Specialist Hospital, Riyadh, 
Saudi Arabia
None available, study completed in 2007
NCT02395952 ns ProKera®, 
Ambiodisk
Not yet recruiting Milton S. Hershey Medical Center, PA, USA Estimated Primary Completion Date: February 2018
NCT02148016 I/II AM Recruiting Sun Yat-sen University, China Estimated Study Completion Date: September 2014, last verified 
May 2014
Limbal stem cell 
deficiency
NCT01377311 I AM Terminated National Taiwan University Hospital, Taiwan Study terminated since technique not used in patients, last verified 
June 2011
NCT00736307 I/II AM Completed Royan Institute, Tehran, Iran None available, Study Completion Date: October 2009, last verified 
April 2010
NCT01562002 I/II AM Completed Instituto Universitario de Oftalmobiología 
Aplicada, Spain
None available, Study Completion Date: December 2014, last verified 
January 2015
NCT01619189 II AM Ongoing Centre Hospitalier National d’Ophtalmologie  
des Quinze-Vingts, France
Primary Completion Date: December 2014, last verified  
February 2015
NCT00491959 I AM Terminated National Taiwan University Hospital, Taiwan Study terminated due to unstable cell sheet quality, thus this 
technique was not used on patients
Ocular surface 
disease and 
reconstruction
NCT00348114 II AM Completed Singapore National Eye Centre, Singapore This study has suspended participant recruitment since 2006
NCT01341223 ns AM Recruiting National Taiwan University Hospital, Taiwan Estimated Primary Completion Date: March 2016, last verified  
March 2012
Dry eye 
syndrome
NCT02369861 I ACCS Recruiting Stemnion, Inc., Pittsburgh, PA, USA Estimated Study Completion Date: December 2015
Glaucoma NCT01551550 II/III AM graft Recruiting Tissue Tech™ Inc., Miami, FL, USA Estimated Study Completion Date: August 2015
The search status as of June 2015 registered on the ClinicalTrials.gov site of U.S. National Institutes of Health (https://clinicaltrials.gov).
ns, not specified; AM, amniotic membrane; ACCS, amnion-derived Cellular Cytokine Solution (Stemnion, Inc.); ProKera® (Tissue Tech™ Inc.) is a device made by a piece of amniotic membrane tissue in between two rings made out of 
flexible material.
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TABLe 2 | Clinical trials using placenta-derived cells, fetal membranes, or derivatives in large wounds.
Condition Clinical trial iD Phase Materials used Status Sponsor Results/status or remarks
Large wound 
epithelialization
NCT01824381 I AM Recruiting Red de Terapia Celular, Spain Estimated Study Completion Date: July 2015, last verified April 2013
NCT01948934 I AM Recruiting Fundacion para la Formacion e Investigacion 
Sanitarias de la Region de Murcia, Spain
Estimated Study Completion Date: June 2015, last verified March 2014
Wounds or 
burns or 
dermatitis
NCT00674999 II/III Amnion Withdrawn The University of Texas Medical Branch, 
Galveston, TX, USA
Study was withdrawn prior to enrolling due to skin bank being destroyed by 
hurricane
NCT00592189 0 Amnion Completed The University of Texas Medical Branch, 
Galveston, TX, USA
None available, Study Completion Date: June 2014, last verified June 2014
NCT00886470 I/II ACCS Terminated Stemnion, Inc., Pittsburgh, PA, USA This study was terminated early due to slow accrual of patients
NCT01715012 II ACCS Terminated Stemnion, Inc., Pittsburgh, PA, USA This study was terminated early due to enrollment futility
NCT02389777 II ACCS Not yet recruiting Stemnion, Inc., Pittsburgh, PA, USA Estimated Study Completion Date: March 2016
NCT01714973 I ACCS Active Stemnion, Inc., Pittsburgh, PA, USA Estimated Study Completion Date: October 2015
NCT02314416* IV Amniotic stem 
cells
Terminated Georgia Regents University, Augusta, GA, 
USA
This study has been withdrawn prior to enrollment
Diabetic foot 
ulcers or 
peripheral 
arterial disease 
or diabetes
NCT02344329 IV Amnion Recruiting University of North Dakota, USA Estimated Study Completion Date: August 2016, last verified January 2015
NCT01859117 I PDA002 Active Celgene Corporation, NJ, USA Ongoing, not recruiting, estimated completion data June 2016
NCT02460081 II PDA002 Recruiting Celgene Corporation, NJ, USA Estimated Study Completion Date: September 2017
NCT02264288 II PDA002 Recruiting Celgene Corporation, NJ, USA Estimated Study Completion Date: June 2018
NCT02399826 ns AM Recruiting Lower Extremity Institute for Research and 
Therapy, OH, USA
Estimated Study Completion Date: January 2016
NCT02461641 ns NuShield, Affinity Recruiting NuCel, LLC, Birmingham, AL, USA Estimated Study Completion Date: September 2016
NCT02209051 IV AMNIOEXCEL Ongoing Derma Sciences, Inc., NJ, USA Estimated Study Completion Date: August 2015 
NCT01693133 ns EpiFix® Recruiting MiMedx® Group, Inc., Marietta, GA, USA Estimated Study Completion Date: July 2015, last verified March 2015
NCT01552499 ns EpiFix® Completed MiMedx® Group, Inc., Marietta, GA, USA Study Completion Date: August 2012, last verified September 2012  
(Zelen et al., 2014)
NCT01657474 ns EpiFix® Completed MiMedx® Group, Inc., Marietta, GA, USA None available, Study Completion Date: November 2013, last verified 
December 2013
NCT01921491 ns EpiFix® Recruiting MiMedx® Group, Inc., Marietta, GA, USA Estimated Primary Completion Date: May 2015
NCT02120755 IV AmnioClear™ Not yet recruiting Liventa Bioscience, Pennsylvania, USA Estimated Primary Completion Date: January 2015, last verified April 2014 
NCT02166294 ns NEOX® CORD 1K Recruiting Amniox Medical, Inc., Atlanta, GA, USA Estimated Study Completion Date: June 2015, last verified July 2014
Venous leg 
ulcers or 
amputation 
wounds
NCT01552447 ns Epifix® Completed MiMedx® Group, Inc., Marietta, GA, USA Study Completion Date: May 2014, last verified November 2013  
(Serena et al., 2014)
NCT02011503 ns Epifix® Recruiting MiMedx® Group, Inc., Marietta, GA, USA Estimated Study Completion Date: January 2016
NCT00820274 II AM Terminated University Hospital, Limoges, France Clinical trial encountered difficulties enrolling a sufficient number of patients
Epidermolysis 
bullosa
NCT02286427 III AM Recruiting Assistance Publique – Hôpitaux de Paris, 
France
Estimated Study Completion Date: January 2019
Laser-
treatment 
induced 
lesions
NCT01895374 ns Bovine AM Completed Seoul National University Hospital,  
South Korea
Study Completion Date: May 2013, last verified July 2013 (Min et al., 2014)
The search status as of June 2015 registered on the ClinicalTrials.gov site of U.S. National Institutes of Health (https://clinicaltrials.gov).
ns, not specified; AM, amniotic membrane; ACCS, amnion-derived Cellular Cytokine Solution (Stemnion, Inc.); NuShield (NuCel, LLC) is a sterilized dehydrated amnion chorion membrane patch, affinity is an aseptically produced, 
hypothermically stored amniotic membrane patch. AMNIOEXCEL® (Derma Sciences) is a dehydrated human amnion-derived tissue allograft. EpiFix® (MiMedx®) is a dehydrated Human Amnion/Chorion Membrane. NEOX® CORD 
(Amniox Medical) is made from cryopreserved human amniotic membrane and umbilical cord. AmnioClear™ (Liventa Bioscience) is an allograft membrane comprising of the amnion and chorion.
TABLe 3 | Clinical trials using placenta-derived cells, fetal membranes, or derivatives in dental and orthopedic defects.
Condition Clinical trial iD Phase Materials used Status Sponsor Results/status or remarks
Dental defects Tooth loss NCT01836783 ns Amnion Recruiting University of Alabama at Birmingham, 
USA
Estimated Study Completion Date: April 2016
NCT02482987 ns BioXclude™ Not yet 
recruiting
Eisenhower Army Medical Center, 
GA, USA
Estimated Study Completion Date: July 2018
Chronic 
periodontitis
NCT02033226 III AM Completed SVS Institute of Dental Sciences, 
India
None available, Study Completion Date: September 2013, last 
verified January 2014 
Gingivitis NCT02071199 I ACCS Recruiting Stemnion, Inc., Pittsburgh, PA, USA Estimated Study Completion Date: August 2015
Orthopedic 
defects
Flexor tendon 
injury
NCT02361814 ns AM graft Recruiting University of Tampere, Finland Estimated Study Completion Date: December 2016
Osteoarthritis NCT02318511 ns ReNu amniotic 
allograft
Recruiting NuCel, LLC, Birmingham, AL, USA Estimated Study Completion Date: March 2017
Plantar fasciitis NCT02427191 II/III AmnioFix® Recruiting MiMedx® Group, Inc., Marietta, GA, 
USA
Estimated Study Completion Date: December 2017
NCT01659827 ns AmnioFix® Completed MiMedx® Group, Inc., Marietta, GA, 
USA
Study Completion Date: March 2013, last verified December 2013 
(Zelen et al., 2013)
NCT01996111 ns EpiFix® Terminated MiMedx® Group, Inc., Marietta, GA, 
USA
Study terminated due to change in regulatory status
Epicondylitis NCT01921569 ns Micronized 
dHACM 
suspension
Terminated MiMedx® Group, Inc., Marietta, GA, 
USA
Study terminated by sponsor, used micronized dehydrated human 
amniotic membrane (dHACM) suspension
Tendon tears NCT01708187 ns Clarix™1k Terminated Orthopedic Foot and Ankle Center, 
OH, USA
Protocol halted due to less than anticipated recruitment
The search status as of June 2015 registered on the ClinicalTrials.gov site of U.S. National Institutes of Health (https://clinicaltrials.gov).
ns, not specified; AM, amniotic membrane; dHACM, dehydrated human amniotic membrane; PAD, peripheral artery disease; ACCS, amnion-derived Cellular Cytokine Solution (Stemnion, Inc.); BioXclude™ (Snoasis Medical, Denver, 
CO, USA) is a human amnion chorion allograft. ReNu™ (NuTech Medical) is a bioactive suspension derived from human amnion and amniotic fluid. AmnioFix® (MiMedx®) is a composite amniotic tissue membrane. PLX-PAD are 
PLacental eXpanded adherent stromal cells (produced by Pluristem Inc.), Clarix™1k (Amniox Medical), C-HAM is a cryopreserved Human Amniotic Membrane.
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TABLe 4 | Clinical trials using placenta-derived cells, fetal membranes, or derivatives in surgery, spinal injuries, and scarring.
Condition Clinical trial iD Phase Materials used Status Sponsor Results/status or remarks
Surgical Post-operative atrial fibrillation NCT02193321 I/II AM patch Recruiting University of Arizona, USA Estimated Study Completion Date: July 2015, 
last verified July 2014
Dorsal cheilectomy procedure for Hallux 
Rigidus
NCT01825356 IV AM Recruiting OrthoCarolina Research Institute, Inc., 
Charlotte, NC, USA
Estimated Study Completion Date:  
December 2016, last verified December 2014
Intrauterine adhesions NCT02132104 ns AM graft Not yet 
recruiting
Capital Medical University, Beijing, China Estimated Study Completion Date:  
November 2016
Adhesions of soft tissue during the 
removal of segmental posterior lumbar 
instrumentation
NCT01357187  ns AmnioFix® Completed MiMedx Group, Inc., Marietta, GA, USA none available, Study Completion Date:  
May 2014, last verified June 2014
Pudendal nerve protection during 
laparoscopic prostatectomies
NCT01832168 ns AmnioFix® Completed MiMedx Group, Inc., Marietta, GA, USA None available, Study Completion Date:  
June 2014, last verified March 2015
Spinal 
injuries
Various spinal injuriesa NCT02070484 ns NuCel® Recruiting OhioHealth, Colombus, OH,USA Estimated Study Completion Date: February 
2016, last verified April 2014
NCT02381067 ns NuCel® Recruiting NuCel, LLC, Birmingham, AL, USA Estimated Study Completion Date: September 
2016
NCT02023372 ns NuCel® Recruiting NuCel, LLC, Birmingham, AL, USA Estimated Study Completion Date: July 2017
Spinal stenosis and herniated disk NCT02380456 ns EpiFix® Recruiting Alexander P. Hughes, MD and MiMedx 
Group, Inc., Marietta, GA, USA
Estimated Study Completion Date: December 
2017
Scarring Scarring post craniectomy NCT02033824 ns EpiFix® Recruiting MiMedx Group, Inc., Marietta, GA, USA Estimated Study Completion Date: June 2016
Scarring post total knee arthroplasty NCT02088567 ns EpiFix® Completed MiMedx Group, Inc., Marietta, GA, USA None available, Study Completion Date: 
October 2014, last verified March 2015
Scarring/spinal stenosis/herniated disk NCT02300909 IV EpiFix® Recruiting MiMedx Group, Inc., Marietta, GA, USA Estimated Study Completion Date: December 
2017
Scarring post laser resurfacing of the face NCT01995604 ns EpiFix® Terminated MiMedx Group, Inc., Marietta, GA, USA This study was withdrawn prior to enrollment
The search status as of June 2015 registered on the ClinicalTrials.gov site of U.S. National Institutes of Health (https://clinicaltrials.gov).
ns, not specified; NuCel® (NuCel, LLC) is a bioactive amniotic suspension derived from human amnion and amniotic fluid. EpiFix® (MiMedx®) is a dehydrated Human Amnion/Chorion Membrane (dHACM). AmnioFix® (MiMedx®) is a 
composite amniotic tissue membrane.
aIncludes: lumbar degenerative disk disease, spinal stenosis, spondylolisthesis, spondylosis, invertebral disk displacement and degeneration, spinal diseases, bone disease.
TABLe 5 | Clinical trials using placenta-derived cells, fetal membranes, or derivatives in other disorders.
Condition Clinical trial iD Phase Materials used Status Sponsor Results/status or remarks
Lung diseases Pulmonary arterial hypertension NCT01795950 I PLX-PAD Recruiting Pluristem Inc., Haifa, Israel Estimated Study Completion Date: September 2016
Pulmonary sarcoidosis NCT01440192 I PDA001 Terminated Celgene Corporation, NJ, USA Study terminated by sponsor
Idiopathic pulmonary fibrosis NCT01385644 I Placental MSC Completed The Prince Charles Hospital, 
Brisbane, QLD, Australia
Study Completion Date: May 2013 (Chambers et al., 2014)
Acute lung injury NCT02175303 I/II Decidual stromal 
cells
Recruiting Karolinska Institutet, Stockholm, 
Sweden
Estimated Study Completion Date: December 2017
Ischemic 
diseases
PAD/peripheral vascular disease/
critical limb ischemia
NCT00951210 I PLX-PAD Completed Pluristem Inc., Haifa, Israel None available, Study Completion Date: October 2011 
NCT01679990 II PLX-PAD Recruiting Pluristem Inc., Haifa, Israel Estimated Primary Completion Date: December 2015
NCT00919958 I PLX-PAD Completed Pluristem Inc., Haifa, Israel None available, Study Completion Date: June 2012
Severe hypoxic–ischemic 
encephalopathy in neonates
NCT02434965 II HPDSC Not yet 
recruiting
New York Medical College, NY, 
USA
Estimated Study Completion Date: December 2019
Acute ischemic stroke NCT01310114 II PDA001 Terminated Celgene Corporation, NJ, USA Study terminated by sponsor
Autoimmune 
diseases
Crohn’s disease NCT01155362 II PDA001 Completed Celgene Corporation, NJ, USA None available, Study Completion Date: April 2014, last 
verified July 2014
NCT01769755 I PDA001 Completed Celgene Corporation, NJ, USA Study Completion Date: November 2014, last verified April 
2015 (Mayer et al., 2013)
Rheumatoid arthritis NCT01261403 II PDA001 Terminated Celgene Corporation, NJ, USA Enrollment terminated pending additional Phase 1 data
Graft versus host disease NCT02172924 I/II Decidual stromal 
cells
Not yet 
recruiting
Karolinska Institutet, Stockholm, 
Sweden
Estimated Study Completion Date: December 2019
Multiple sclerosis Not applicable – PDA001 Published 
study
– Lublin et al. (2014)
Diabetes Not applicable – Placenta-derived 
MSC
Published 
study
– Jiang et al. (2011)
Hematological 
malignancies
Variousa NCT00596999 I HPDSC Enrolling Celgene Corporation, NJ, USA Estimated Study Completion Date: December 2013, last 
verified November 2007
Variousb NCT01586455 I HPDSC Recruiting New York Medical College,  
NY, USA
Estimated Study Completion Date: December 2019
Hemorrhagic 
cystitis
– NCT02172963 I/II Decidual stromal 
cells
Completed Karolinska Institutet, Stockholm, 
Sweden
None available, study completed December 2013
– NCT02174536 II Decidual stromal 
cells
Recruiting Karolinska Institutet, Stockholm, 
Sweden
Estimated Study Completion Date: December 2016
Peyronie’s 
disease
– NCT02395029 I PMD-MSC Completed Melissa Marchand from Z Urology, 
Coral Springs, FL, USA
None available, Study completed in March 2015
Erectile 
dysfunction
– NCT02398370 I PMD-MSC Completed Melissa Marchand from Z Urology, 
Coral Springs, FL, USA
None available, Study completed in March 2015
The search status as of June 2015 registered on the ClinicalTrials.gov site of U.S. National Institutes of Health (https://clinicaltrials.gov).
ns, not specified; AM, amniotic membrane; PMD-MSC, placental matrix-derived mesenchymal stem cells; PLX-PAD are PLacental eXpanded adherent stromal cells (produced by Pluristem Inc.), Clarix™1k (Amniox Medical), HPDSC 
(human placenta-derived stem cells produced by Celgene Cellular Therapeutics), PDA001 are human placenta-derived adherent cells (Celgene Corporation).
aIncludes: myelodysplastic syndrome, acute myelogenous/lymphocytic, leukemia, sickle cell disease, beta thalassemia, inborn errors of metabolism, severe combined immunodeficiency disease.
bIncludes: mucopolysaccharidosis I, mucopolysaccharidosis VI, adrenoleukodystrophy, Niemann–Pick disease, metachromatic leukodystrophy, Wolman disease, Krabbe’s disease, Gaucher’s disease, fucosidosis, Batten disease, 
severe aplastic anemia, Diamond–Blackfan anemia, amegakaryocytic thrombocytopenia, myelodysplastic syndrome, acute myelogenous leukemia, acute lymphocytic leukemia.
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important in underlining the safety of placental cells in treating 
patients with multiple sclerosis, and encourages future studies 
to investigate therapeutic benefit in this physical and mental 
disabling condition.
PDA002 cells are currently being tested for the treatment of 
patients with diabetic foot ulcers and peripheral arterial disease 
(NCT01859117, active; NCT02460081, recruiting; NCT02264288, 
recruiting) (Table  2). Human placenta-derived stem cells 
(HPDSC, also produced by Celgene Cellular Therapeutics) are 
obtained from placenta perfusion after removal non-viable and 
red blood cells and tissue debris. These cells are cryopreserved 
without culture expansion (Kang et al., 2013). HPDSC will soon be 
investigated for treating neonates with severe hypoxic–ischemic 
encephalopathy (NCT02434965, not yet recruiting), and patients 
with hematological malignancies (NCT00596999, enrolling; 
NCT01586455, recruiting) (Table 5).
Placental-derived MSC are isolated from the placental tissues 
after the removal of umbilical cord and external membranes 
by enzymatic digestions (Prince Charles Hospital in Brisbane, 
Australia) (Brooke et al., 2009). The safety of placental-derived 
MSC has been studied in patients with idiopathic pulmonary 
fibrosis (IPF, NCT01385644, completed). The results of this study 
have recently been published and show that intravenous infusion 
of 2 million cells per kilogram is safe in patients with moderate 
to severe IPF. Of note, the possibility of embolization of cells 
in the compromised pulmonary vascular bed, a major concern 
during this type of treatment, did not lead to major adverse clini-
cal outcomes. Only minor, transient changes in hemodynamics 
and gas exchange, and only minor adverse events were observed 
(Chambers et al., 2014).
Placenta-derived decidual stromal cells can be isolated by 
either trypsin digestion or tissue explants (Karolinska Institutet, 
Sweden). These cells derive from the decidua parietalis and are 
of maternal origin (Ringden et  al., 2013; Erkers et  al., 2015). 
They have been tested in a pilot study in patients with hemor-
rhagic cystitis (NCT02172963, completed) and will soon be 
investigated in a different clinical trial to treat the same disease 
(NCT02174536, recruiting) (Table 5). A clinical trial is also due 
to begin for the treatment of patients with Graft versus Host 
Disease (NCT02172924, not yet recruiting). Moreover, a pilot 
study is currently recruiting patients with acute lung injury to 
evaluate the safety of placenta DSCs (NCT02175303, recruiting) 
(Table 5).
Remarkably, encouraging results have been published for 
studies using placenta-derived cells in patients with types 
II diabetes (Table  5) (Jiang et  al., 2011). In this Phase I study 
aimed at evaluating the safety of placenta-derived MSC, 10 
patients with type 2 diabetes were given 3 intravenous infusions 
at the 1-month intervals. The authors reported that the mean 
insulin requirement was significantly reduced at the 3-month 
follow-up, and no side effects (fever, chills, liver damage) were 
documented. This trial could represent a turning point in the 
use of placental cells, since it is the first to document their use 
in patients with diabetes. A different study of particular inter-
est was recently published investigating the immunogenicity of 
placenta decidual stromal cells in combination with AM in an 
11-month-old patient with epidermolysis bullosa (Kaipe et  al., 
2015), showing improved healing of blisters and wounds, but at 
the same time warranting further investigations on the immuno-
genicity of these cells.
Notably, other clinical trials have and are currently investigat-
ing placental cell derivatives and, in particular amnion-derived 
cellular cytokine solution (ACCS) (Stemnion, Inc., Pittsburgh, PA, 
USA). ACCS is obtained from amniotic cell culture (Bergmann 
et al., 2009), and contains factors relevant for wound healing, such 
as platelet-derived growth factor (PDGF), vascular endothelial 
growth factor (VEGF), angiogenin, TGF-β2, TIMP-1, and 
TIMP-2 (Steed et al., 2008). It is currently being tested in patients 
with radiation-induced dermatitis (NCT01714973, active), and 
a separate trial is due to begin in patients with UV-induced 
burns (NCT02389777, not yet recruiting), (Table 2). Moreover, 
other trials are currently recruiting patients to test ACCS in 
dry eye syndrome (NCT02369861, recruiting, Table  1), and 
gingivitis (NCT02071199, recruiting, Table  3). Two trials, the 
first aimed at investigating ACCS in partial thickness wounds 
(NCT00886470), and the second in patients with deep burns 
(NCT01715012), were terminated due to difficulties in enrolling 
patients (Table 2).
Another placenta-derived product, amniotic membrane 
extract (AMX), which is based on lyophilized human AM for 
topical application, is under investigation in persistent corneal 
epithelial defects and has shown promising results for reducing 
epithelial defects (Kordić et al., 2013).
MeCHANiSMS OF ACTiON: THe QUeST 
FOR SCieNTiFiC RATiONALe
Evidence of long-term survival with no signs of immune reaction 
was provided many years ago when the AM was used as an allo-
graft under skin (Douglas et al., 1954) or in the peritoneal cavity 
(Trelford et al., 1974). Subsequently, a glycoprotein from amnion 
was reported to be responsible for suppressing “foreign body” 
reactions by acting on lymphocytes and preventing lymphoblas-
togenesis (McIntyre and Faulk, 1979).
Since then, numerous mechanisms have been put forth, either 
to explain the therapeutic effects of the intact or decellularized 
AM or those of isolated placental cells. Nowadays, the clinical 
potential of placenta-derived cells essentially relies on their parac-
rine mechanisms able to induce anti-inflammatory responses and 
re-epithelialization, and also to possess pro- or anti-angiogenic 
properties. Below we will briefly discuss these aspects.
Anti-inflammatory Properties
Among the paracrine actions underlying the anti-inflammatory 
effect of placenta-derived cells are their interactions with immune 
cells of innate and adaptive immunity. Indeed, many studies have 
reported the ability of placenta-derived cells to suppress the 
proliferation of activated T cells (Bailo et al., 2004; Chang et al., 
2006; Wolbank et  al., 2007; Prasanna et  al., 2010; Kronsteiner 
et al., 2011a,b), reduce Th1 inflammatory cytokines and induce T 
regulatory cells (Raicevic et al., 2011; Ohshima et al., 2012; Anam 
et al., 2013; Parolini et al., 2014; Pianta et al., 2015), and target B 
lymphocytes (Li et al., 2005; Ma et al., 2012). Furthermore, they can 
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also influence antigen presenting cells by blocking differentiation 
of monocytes to dendritic cells (Magatti et al., 2009; Tipnis et al., 
2010; Kronsteiner et al., 2011a,b; Saeidi et al., 2013; Banas et al., 
2014; Abomaray et al., 2015; Donders et al., 2015; Magatti et al., 
2015), and induce M2 macrophage differentiation (Manuelpillai 
et al., 2012; Abumaree et al., 2013; Magatti et al., 2015). Moreover, 
placenta-derived cells have been shown to inhibit neutrophils 
(Zhou et al., 2003; Li et al., 2005; Chen et al., 2014), and natural 
killer cells (Ribeiro et al., 2013; Chatterjee et al., 2014; Li et al., 
2015).
Even though the underlying mechanisms are not completely 
understood, there are numerous studies which have put forth 
different hypotheses. Herein, we will briefly summarize them, 
since comprehensive reviews of the interactions between 
placenta-derived and immune cells have been described else-
where (Parolini et  al., 2009; Parolini et  al., 2010; Manuelpillai 
et  al., 2011; Parolini and Caruso, 2011; Prasanna and Jahnavi, 
2011; Abumaree et al., 2012; Caruso et al., 2012; La Rocca et al., 
2012; Kim et al., 2013; Silini et al., 2013; Insausti et al., 2014). 
Cells from placental tissues have been shown to produce factors 
shown to dampen inflammation, such as interleukin (IL)-10 
(Kronsteiner et al., 2011a,b; Rossi et al., 2012; Abomaray et al., 
2015; Magatti et al., 2015), transforming growth factor (TGF)-β 
(Liu et al., 2012; Rossi et al., 2012; Pianta et al., 2015), hepato-
cyte growth factor (HGF) (Najar et al., 2010; Kronsteiner et al., 
2011a,b; Raicevic et al., 2011; Yamahara et al., 2014), prostaglan-
din E2 (PGE2), (Whittle et  al., 2000; Chen et  al., 2010; Najar 
et al., 2010; Kronsteiner et al., 2011a,b; Raicevic et al., 2011; Liu 
et al., 2012; Rossi et al., 2012; Liu et al., 2014; Yamahara et al., 
2014; Abomaray et al., 2015), and indoleamine 2,3-dioxygenase 
(IDO) enzyme (Chang et al., 2006; Rossi et al., 2012; Anam et al., 
2013; Donders et  al., 2015). Moreover, placenta-derived cells 
express negative co-signaling proteins B7H3, PD-L1 (CD274), 
and PD-L2 (CD273), (Petroff and Perchellet, 2010; Tipnis et al., 
2010; Kronsteiner et al., 2011a,b; La Rocca et al., 2012; Abumaree 
et al., 2013; Wu et al., 2014). HLA-G, a molecule known to have 
immune-regulatory properties through its interactions with 
immunoglobulin-like transcript (ILT) receptors (ILT-2, ILT-3, 
ILT-4), (Allan et al., 2000; Hunt et al., 2005), has been reported to 
be secreted by a variety of placenta-derived cells (Lefebvre et al., 
2000; Chang et al., 2006; Banas et al., 2008; Roelen et al., 2009; 
Kronsteiner et  al., 2011a,b; Pratama et  al., 2011; Anam et  al., 
2013; Donders et al., 2015).
On another note, inflammatory cytokines/milieu have 
been shown to enhance the immunomodulatory properties 
of placenta-derived cells. For example, interferon (IFN)-γ has 
been shown to enhance their anti-proliferative properties on 
PBMC (Chang et  al., 2006; Prasanna et  al., 2010; Kronsteiner 
et  al., 2011a,b; Donders et  al., 2015). IFN-γ has also been 
shown to increase HLA-G (Lefebvre et  al., 2000; Banas et  al., 
2008; Kronsteiner et  al., 2011a,b), PD-L1 and PD-L2 (Banas 
et  al., 2008; Petroff and Perchellet, 2010; Tipnis et  al., 2010; 
Kronsteiner et al., 2011a,b), and PGE2 production by placental 
cells (Chen et al., 2010). Moreover, IL-1β, a potent inflamma-
tory cytokine, has also been shown to enhance the immune 
modulatory properties of placental cells, such as through the 
induction of PGE2 secretion (Mitchell et al., 1993; Fukuda et al., 
1999; Pomini et al., 1999; Chen et al., 2010, Phillips et al., 2011), 
and by enhancing their suppressive activities toward NK cells 
(Chatterjee et al., 2014).
Pro- and Anti-Angiogenic Properties
The intact AM has been shown to produce an array of anti-
angiogenic factors. This property is epitomized in the use of 
intact AM for corneal surface reconstruction, where the use 
of AM decreases vascularization of the ocular surface through 
the production of anti-angiogenic proteins (Kim and Tseng, 
1995; Shao et al., 2004), such as pigment epithelium-derived 
factor (PEDF), (Kim and Tseng, 1995; Dawson et  al., 1999; 
Shao et  al., 2004), tissue inhibitor of metalloproteinase 
(TIMP)-1 and TIMP-2 (Hao et al., 2000), and thrombospon-
din-1 (TSP-1), (Zaslavsky et  al., 2010). The intact AM has 
also been reported to have a large amount of ECM proteins 
(i.e., laminin-1, laminin-5, fibronectin), which are involved in 
the suppression of neovascularization in the cornea (Fukuda 
et al., 1999).
Decellularized AM, whereby amniotic epithelial cells are 
eliminated and the cytokine-rich ECM is retained, has been 
shown to maintain anti-angiogenic properties (Tseng et al., 2004).
Furthermore, epithelial and mesenchymal cells isolated from 
the AM have also been shown to produce anti-angiogenic factors, 
such as TIMP-1, TIMP-2, TSP-1, and endostatin (Rowe et  al., 
1997; Hao et al., 2000).
On the other hand, pro-angiogenic properties have also been 
attributed to the AM, which can be considered important con-
tributors to its wound healing and regenerative capabilities. For 
example, cytokines known to promote angiogenesis have been 
found in dehydrated human amnion/chorion membrane, such as 
angiopoietin-2, epidermal growth factor (EGF), basic fibroblast 
growth factor (bFGF), heparin binding epidermal growth factor 
(HB-EGF), HGF, platelet-derived growth factor BB (PDGF-BB), 
placental growth factor (PlGF), and VEGF (Koob et al., 2014b). 
Recently, pro-angiogenic factors have been found in conditioned 
medium from MSC isolated from the AM, which was shown to 
not only limit infarct size but also promote capillary formation 
at the infarct border zone when injected into infarcted rat hearts 
(Danieli et al., 2015). These apparently contradictory properties 
could give rise to the importance of understanding the impact of 
the microenvironment in determining the pro- or anti-angiogenic 
abilities of the AM and placental cells.
Promotion of epithelialization
Another important, and well-documented, property of the intact 
AM is its ability to promote re-epithelialization. The intact AM 
has been used as a basement membrane to promote epithelial 
cell migration, differentiation, and prevent epithelial cell apop-
tosis (Dua et al., 2004). In addition, it produces factors that can 
stimulate epithelialization, such as bFGF, HGF, and TGFβ (Dua 
and Azuara-Blanco, 1999; Koizumi et al., 2000). The intact AM 
also produces factors that support the growth and differentiation 
of stem and progenitor cells (Meller et al., 2000; Meller et al., 2002, 
Insausti et al., 2010), such as keratinocyte growth factor (KGF) 
(Casey and MacDonald, 1997), supporting its use as a progenitor 
cell niche (Tseng et al., 2004).
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CONCLUDiNG ReMARKS
Although there are still many open questions regarding the 
sine qua non conditions for the clinical use of placental cells 
(Fierabracci et al., 2015), the increasing number of clinical trials 
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